跳至主要内容

Medicilon congratulates - Treatable and Accessible! Adult and adolescent Type A and Type B influenza! AnDiCon Bio's pill cures influenza with the new drug Madoxanavir - Phase III successful research

 On April 29th, AnDiCon Bio (AnDiCon) announced that the Phase III clinical trial of the new influenza drug Madoxanavir tablets (ADC189), which cures Type A and Type B influenza in adults and adolescents, has reached its primary endpoint, demonstrating excellent safety and efficacy."

Medicilon, as a partner of AnDiCon, provided formulation research services for the 'pediatric version' of the anti-influenza Class 1 Madoxanavir granules for influenza, assisting in its rapid advancement in preclinical research and development processes. This progress of Madoxanavir tablets not only validates its effectiveness and safety in treating influenza in adults and adolescents, but also indicates its enormous potential in the field of influenza treatment in children.

Andicon.webp

About AnDiCon Bio

The AnDiCon Bio Innovation Team, led by several academicians, focuses on the fields of respiratory anti-infection and pain.  The company has gathered a group of academic professionals and highly efficient and pragmatic senior talents at different stages of new drug development, including innovative drug design and synthesis, DMPK technology research and application, and research and development of high-end formulations suitable for special populations. AnDiCon Bio relies on the company's DMPK platform to establish a new drug R&D system based on metabolic differentiation. In addition to the anti-influenza new drug pipeline ADC189, the company's product pipeline also includes a variety of innovative drugs for respiratory pathogens, such as the anti-respiratory syncytial virus (RSV) drug ADC789 suspension, the novel anti-chlamydia super antibiotic ADC101 suspension, and innovative drugs like ADC308 tablets expected to fill the domestic gap in the treatment of endometriosis and uterine fibroids.  In 2022, the company completed a Pre-A round financing of RMB 100 million. In 2023, the company received strategic investment of tens of millions of RMB from Simcere Pharmaceutical (2096.HK). Since 2024, the company has completed a Series A financing of several hundred million RMB.  Looking forward, the company hopes to obtain more support and empowerment from investment institutions, accelerate the progress of innovative drug research and development, bring new treatment options to patients as soon as possible, and bring Chinese wisdom and solutions that are "healable" and accessible to China's public health security.

标签：
地点: 美国

评论

发表评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...
发表评论
阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...
发表评论
阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文